Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
about
Interventions for preventing neuropathy caused by cisplatin and related compoundsInterventions for preventing neuropathy caused by cisplatin and related compoundsInterventions for preventing neuropathy caused by cisplatin and related compoundsγ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current StatusVitamin E Analogs as Radiation Response ModifiersPre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in miceWR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.Effect of dexrazoxane and amifostine on the vertebral bone quality of Doxorubicin treated male ratsAntioxidants reduce consequences of radiation exposure.THE POTENTIATION OF THE RADIOPROTECTIVE EFFICACY OF TWO MEDICAL COUNTERMEASURES, GAMMA-TOCOTRIENOL AND AMIFOSTINE, BY A COMBINATION PROPHYLACTIC MODALITY.Efficacy of Drug Interventions for Chemotherapy-Induced Chronic Peripheral Neurotoxicity: A Network Meta-analysisRadiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-beta1-mediated tissue fibrosis.WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.Oxidative stress, redox regulation and diseases of cellular differentiation.Radiation countermeasure agents: an update (2011-2014)Quantitative histologic evidence of amifostine-induced cytoprotection in an irradiated murine model of mandibular distraction osteogenesis.Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin.Combination of radiotherapy and chemotherapy in locally advanced NSCLC.Amifostine Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Apoptosis and Oxidative StressThe impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute.Animal models for acute radiation syndrome drug discovery.A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in larL-Carnitine Protection Against Cisplatin Nephrotoxicity In Rats: Comparison with Amifostin Using Quantitative Renal Tc 99m DMSA Uptake.Efficacy of royal jelly on methotrexate-induced systemic oxidative stress and damage to small intestine in rats.Development and Validation of an HPLC Method for Determination of Amifostine and/or Its Metabolite (WR-1065) In Human Plasma Using OPA Derivatization and UV Detection.Amifostine-antioxidant drug in anticancer therapy.Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF.Effects of amifostine in combination with cyclophosphamide on female reproductive system.Developing better mouse models to study cisplatin-induced kidney injury.Examination of the effect of ovarian radiation injury induced by hysterosalpingography on ovarian proliferating cell nuclear antigen and the radioprotective effect of amifostine: an experimental study.
P2860
Q24197763-951758F3-9192-4DFB-95F5-945160EA8DA8Q24236661-04A5350B-7550-4747-A233-1250274A3AF5Q24246530-B58DC967-32F0-4C80-B622-DDD08BA6D171Q26751505-092CAD79-6603-4AA8-BFD8-037A981199EDQ26781114-0DB59C38-202B-4A38-B28D-D8A11B24A578Q28486646-30D65FF9-6E0C-46DC-AEC8-F2817A8DA99EQ30492649-1ADF79C6-3CEA-4C62-8FD9-0DFECF713B5BQ33455575-8651736F-F458-481F-8813-67BB46DA201BQ33565586-5E070413-4DAF-41D9-8DF6-D2EC8FED1DC5Q33728050-3950B072-A4E1-4B8C-B08D-E3FEB535A332Q33774892-D35F3F2B-B756-452E-B36F-9CF59BBA2D2DQ34149752-BE97D886-BD33-4C4E-A489-59ABF7E51A79Q35394336-0B7E9DF3-C152-419A-AE6B-B780015318C3Q35566671-7B01BE59-59B6-483F-BE8E-C8667B32D0BBQ35611511-0237B212-C29A-47C4-911D-0DC8451D63F3Q35626587-4BC34706-0A85-43A9-BB6D-F86490313306Q36438246-E5F925E9-94B6-46D1-A411-16C532F25544Q36544184-F4BD9CF8-835D-4A21-8BFD-986271F65B13Q37259938-2D38630A-24C3-4F94-9F3D-2F43293F2A5BQ37614572-527B9F90-9E34-4671-985A-A144B0BABF9DQ37723707-C2A242FB-C4AF-4FA8-ADA3-8D1037EC7E92Q37800633-2FBAEE77-6E40-4E2B-A650-E1B910CF6D7CQ37970729-56B8BF43-915F-4B07-9E0C-D0D8F8BB14CDQ38394740-38F17834-CCDA-4D66-BC9F-E4F300011D47Q38665691-76D13ACA-D7A4-4F91-B752-4938995BD9F1Q41491887-4107D917-0BE1-449A-B12C-2039D8DF9DA4Q42068866-A5CF3F78-8467-45BB-8E56-3685E7C7F579Q42202938-64FE4B2F-2335-4B94-BC3E-3F79DC6C2D97Q43215671-93597368-61B7-46CA-BF4E-25B2BB107553Q46910828-79349875-DBDC-4F1B-8446-ACE42B123F74Q48656914-BC24C90C-6B54-427F-B447-2A8EA1EFE1C3Q53154188-3879AB9A-0BE1-43D8-9794-C0BB079A65C2Q55255721-88FFE574-2425-49F3-9A04-E427C3E2ED9D
P2860
Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@ast
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@en
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@nl
type
label
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@ast
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@en
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@nl
prefLabel
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@ast
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@en
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@nl
P1433
P1476
Amifostine: an update on its c ...... n in myelodysplastic syndrome.
@en
P2093
P304
P356
10.2165/00003495-200161050-00012
P577
2001-01-01T00:00:00Z
P5875
P6179
1031267906